ClinicalTrials.gg

TargetBeta

APP

amyloid beta precursor protein · also alpha-sAPP, AD1 · Receptor ligands

3 programs in company-led studies act on APP, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
donanemabruleEli Lillyphase 4147 running–ChEMBL
ABBV-1758AbbViephase 211 running–the company's pipeline
ALIA-1758AbbViephase 110 running–the company's pipeline

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.